# Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

> **NCT02005848** · PHASE2 · COMPLETED · sponsor: **Kamada, Ltd.** · enrollment: 70 (actual)

## Conditions studied

- New Onset Type-1 Diabetes

## Interventions

- **BIOLOGICAL:** Alpha-1 Antitrypsin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02005848
- **Lead sponsor:** Kamada, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2018-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02005848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02005848, "Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02005848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*